

### **AMENDMENTS TO THE CLAIMS**

Amendments to the claims, if any, are reflected in the following listing of claims, which replaces all prior versions and listings of claims in the application:

#### **Listing of Claims:**

Claims 1-60 (canceled)

61. (previously presented) A method of assessing susceptibility to myocardial infarction (MI) in a human individual, the method comprising:

screening nucleic acid of the individual to determine whether the nucleic acid comprises a 5-lipoxygenase activating protein (FLAP) haplotype that comprises polymorphisms SG13S114, allele T; SG13S32, allele A; SG13S25, allele G; and SG13S89, allele G;

wherein the presence of the haplotype in the nucleic acid of the individual identifies the individual as having elevated susceptibility to MI, and wherein the absence of the haplotype in the nucleic acid of the individual identifies the individual as not having the elevated susceptibility to MI due to the haplotype.

62. (withdrawn) The method of claim 61, wherein the haplotype further comprises polymorphism SG13S99, allele T.

63. (Canceled)

64. (Canceled)

65. (Previously presented) The method of claim 61 or 62, comprising obtaining a biological sample from the individual that comprises the nucleic acid, and screening the nucleic acid from the biological sample.

66. (Previously presented) The method of claim 61 or 62, wherein the screening step comprises subjecting said nucleic acid to at least one procedure selected from

the group consisting of: (a) enzymatic amplification of nucleic acid from the individual; (b) electrophoretic analysis; (c) restriction fragment length polymorphism analysis; and (d) nucleotide sequence analysis.